Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by H. Lee Moffitt Cancer Center and Research Institute
Sponsor:
Collaborators:
GlaxoSmithKline
Celgene Corporation
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01496976
First received: December 16, 2011
Last updated: October 15, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 2016
  Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)